Skye Bioscience (SKYE) Free Cash Flow (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Free Cash Flow of -$8.5 million for Q1 2026, up 7.09% year-over-year from -$8.0 million in Q1 2025, and up 12.5% quarter-over-quarter from -$9.8 million in Q4 2025.
Skye Bioscience (SKYE) Free Cash Flow (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Free Cash Flow for 15 consecutive years, with -$8.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 7.09% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$42.4 million (down 42.49% YoY), while the FY2025 annual figure was -$43.1 million, down 70.32% from the prior year.
- Free Cash Flow advanced to -$8.5 million in Q1 2026 per SKYE's latest filing, from -$9.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.0 million in Q2 2023 and bottomed at -$13.4 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$6.1 million across 5 years, with a median of -$4.7 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 31.42% — and 2024, when it tumbled 257.76%.
- Skye Bioscience's Free Cash Flow stood at -$3.9 million in 2022, then climbed by 2.29% to -$3.9 million in 2023, then plunged by 72.78% to -$6.7 million in 2024, then plunged by 46.45% to -$9.8 million in 2025, then climbed by 12.5% to -$8.5 million in 2026.
- Business Quant data shows SKYE's Free Cash Flow at -$8.5 million in Q1 2026, -$9.8 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - | -7.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.54 Mn |
| Mar 31, 2026 | -8.54 Mn |
| Dec 31, 2025 | -9.76 Mn |
| Dec 31, 2025 | -9.76 Mn |
| Sep 30, 2025 | -13.36 Mn |
| Sep 30, 2025 | -13.36 Mn |
| Jun 30, 2025 | -10.75 Mn |
| Jun 30, 2025 | -10.75 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Mar 31, 2025 | -9.19 Mn |
| Dec 31, 2024 | -6.66 Mn |
| Dec 31, 2024 | -6.66 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -7.13 Mn |
| Jun 30, 2024 | -7.13 Mn |
| Mar 31, 2024 | -4.71 Mn |
| Mar 31, 2024 | -4.71 Mn |
| Dec 31, 2023 | -3.86 Mn |
| Dec 31, 2023 | -3.86 Mn |